You are here: Industry Insights > Immuno-Oncology

News List

Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion biospace
March 04, 2020
Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards.
Bicycle Therapeutics and Genentech sign $1.7bn cancer therapies deal pharmaceutical-technology
March 04, 2020
Bicycle Therapeutics has signed an agreement with Roche subsidiary Genentech for the discovery, development and commercialisation of immuno-oncology therapies.
Sanofi announces it will acquire Synthorx for $2.5 billion europeanpharmaceuticalreview
December 16, 2019
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline pharmaceutical-business-review
December 12, 2019
Sanofi has agreed to acquire US-based clinical-stage biotechnology company Synthorx for about $2.5bn in an all-cash deal in a move to strengthen its immuno-oncology (IO) pipeline.
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration En-CPhI.CN
November 18, 2019
3SBio Inc. and Verseau Therapeutics, Inc. announced the selection of VTX-0811, a monoclonal antibody targeting PSGL-1, as the first licensed program under their partnership agreement focused ...
Regen BioPharma Files Immuno-Oncology Patent Application americanpharmaceuticalreview
August 09, 2019
Regen BioPharma has announced the filing of a US patent application covering a newly discovered synergy between inhibition of NR2F6 and cannabidiol (CBD). The new data demonstrates enhanced ability to reduce cancer growth in ...
Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets firstwordpharma
May 10, 2019
The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology
Boehringer partners PureTech to develop immuno-oncology candidates pharmaceutical-technology
April 24, 2019
Boehringer partners PureTech to develop immuno-oncology candidates.
Bringing CAR-T to solid tumors with help from alpacas fiercebiotech
April 17, 2019
CAR-T therapies made from individual patients’ immune cells have revolutionized the treatment of some blood cancers, but they’ve been difficult to translate to solid tumors.
Keytruda spurs long responses in small cell lung cancer fiercepharma
April 10, 2019
ATLANTA—Merck & Co. is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page